The approval of Bruton tyrosine kinase (BTK) inhibitor ibrutinib and PI3K inhibitor idelalisib has revolutionized chronic lymphocytic leukemia (CLL) therapy (1–4). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.